MALCOLM BRENNER to Neoplasms
This is a "connection" page, showing publications MALCOLM BRENNER has written about Neoplasms.
Connection Strength
3.696
-
Emerging Challenges to Cellular Therapy of Cancer. Cancer J. 2023 Jan-Feb 01; 29(1):20-27.
Score: 0.301
-
Immunotherapy against cancer-related viruses. Cell Res. 2017 Jan; 27(1):59-73.
Score: 0.198
-
A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy. Stem Cell Reports. 2015 Oct 13; 5(4):597-608.
Score: 0.181
-
Gene-modified cells for stem cell transplantation and cancer therapy. Hum Gene Ther. 2014 Jul; 25(7):563-9.
Score: 0.167
-
Is cancer gene therapy an empty suit? Lancet Oncol. 2013 Oct; 14(11):e447-e456.
Score: 0.159
-
Will T-cell therapy for cancer ever be a standard of care? Cancer Gene Ther. 2012 Dec; 19(12):818-21.
Score: 0.148
-
Cellular therapy for cancer: let there be light. Tissue Antigens. 2012 Jan; 79(1):1-3.
Score: 0.140
-
T cell receptors and cancer: gain gives pain. Nat Med. 2010 May; 16(5):520-1.
Score: 0.125
-
Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010 Apr; 22(2):251-7.
Score: 0.123
-
Cellular immunotherapy of cancer. Methods Mol Biol. 2010; 651:319-45.
Score: 0.122
-
Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am Soc Hematol Educ Program. 2009; 675-81.
Score: 0.114
-
The clone ranger? Mol Ther. 2008 Sep; 16(9):1520-1.
Score: 0.111
-
Developing T-cell therapies for cancer in an academic setting. Adv Exp Med Biol. 2008; 610:88-99.
Score: 0.106
-
A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle. 2005 Feb; 4(2):203-5.
Score: 0.087
-
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 Jan; 637(8047):940-946.
Score: 0.086
-
Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood. 2004 Oct 15; 104(8):2272-80.
Score: 0.083
-
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023 03 29; 9(13):eade6790.
Score: 0.077
-
Chimeric T-cell receptors for the targeting of cancer cells. Acta Haematol. 2003; 110(2-3):154-9.
Score: 0.075
-
Cancer vaccines: dream, reality, or nightmare? Clin Exp Med. 2002 Nov; 2(3):109-18.
Score: 0.074
-
Targeting glycans for CAR therapy: The advent of sweet CARs. Mol Ther. 2022 09 07; 30(9):2881-2890.
Score: 0.073
-
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
Score: 0.073
-
Cancer vaccines. Hematol Oncol Clin North Am. 2001 Aug; 15(4):741-73.
Score: 0.068
-
Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8a?-engineered human CD4+ T cells. Sci Adv. 2020 07; 6(27):eaaz7809.
Score: 0.063
-
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Mol Ther. 2020 05 06; 28(5):1251-1262.
Score: 0.062
-
"Resistance is futile". Gene Ther. 1999 Oct; 6(10):1646-7.
Score: 0.060
-
Adoptive Cell Therapy: ACT-Up or ACT-Out? Mol Ther. 2019 04 10; 27(4):693-694.
Score: 0.058
-
Use of gene marking technologies in oncology. Forum (Genova). 1998 Oct-Dec; 8(4):342-53.
Score: 0.056
-
Gene transfer and the treatment of childhood cancer. Cancer Invest. 1998; 16(4):269-78.
Score: 0.053
-
Gene and cell transfer for specific immunotherapy. Vox Sang. 1998; 74 Suppl 2:87-90.
Score: 0.053
-
Next Steps in the CAR Journey of a Thousand Miles. Mol Ther. 2017 10 04; 25(10):2226-2227.
Score: 0.052
-
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017 04 15; 77(8):2040-2051.
Score: 0.050
-
Transfer of marker genes into hemopoietic progenitor cells. Cytokines Mol Ther. 1996 Sep; 2(3):193-200.
Score: 0.049
-
3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirus. Biomaterials. 2016 Apr; 84:76-85.
Score: 0.046
-
The contribution of marker gene studies to hemopoietic stem cell therapies. Stem Cells. 1995 Sep; 13(5):453-61.
Score: 0.045
-
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014 Jan; 257(1):107-26.
Score: 0.040
-
Engineered T cells for cancer treatment. Cytotherapy. 2014 Jun; 16(6):713-33.
Score: 0.040
-
Highlights of the second international conference on "Immunotherapy in Pediatric Oncology". Pediatr Hematol Oncol. 2011 Sep; 28(6):459-60.
Score: 0.034
-
Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther. 2009 Oct; 9(5):396-408.
Score: 0.030
-
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008 Jun; 31(5):500-5.
Score: 0.027
-
The continuing contribution of gene marking to cell and gene therapy. Mol Ther. 2007 Apr; 15(4):666-76.
Score: 0.025
-
Options for T-cell based therapies. Vox Sang. 2004 Jul; 87 Suppl 2:230-4.
Score: 0.021
-
Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids. Mol Ther. 2004 Apr; 9(4):489-95.
Score: 0.021
-
[Gene therapy of childhood cancers: current status and perspectives]. Bull Cancer. 2003 Mar; 90(3):227-38.
Score: 0.019
-
Gene marking. Gene Ther. 1996 Apr; 3(4):278-9.
Score: 0.012
-
Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation. Hum Gene Ther. 1996 Mar 20; 7(5):655-67.
Score: 0.012
-
Vectors in cancer therapy: how will they deliver? Cancer Gene Ther. 1995 Dec; 2(4):291-7.
Score: 0.012
-
European School of Oncology position paper. Gene therapy for the medical oncologist. Eur J Cancer. 1995; 31A(9):1531-7.
Score: 0.011
-
Gene transfer into human hemopoietic progenitor cells. Br Med Bull. 1995 Jan; 51(1):167-91.
Score: 0.011
-
Continuous infusion of interleukin-2 in children with refractory malignancies. Cancer. 1993 Jul 15; 72(2):623-8.
Score: 0.010
-
IL-4 acts as a homeostatic regulator of IL-2-induced TNF and IFN-gamma. Immunology. 1991 Feb; 72(2):161-6.
Score: 0.008
-
Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol Ther. 2008 Mar; 16(3):599-606.
Score: 0.007
-
Progress and prospects: gene therapy clinical trials (part 2). Gene Ther. 2007 Nov; 14(22):1555-63.
Score: 0.007
-
Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Dec 01; 7(18):2287-313.
Score: 0.003
-
Psychological effects of bone marrow transplantation on children and adolescents: preliminary report of a longitudinal study. Bone Marrow Transplant. 1995 Jun; 15(6):829-35.
Score: 0.003
-
Measurement of red blood cell-vitamin B12: a study of the correlation between intracellular B12 content and concentrations of plasma holotranscobalamin II. Am J Hematol. 1993 Jul; 43(3):226-9.
Score: 0.002
-
Immunofluorescent studies of human leukemic cells with antiserum to a murine leukemic virus (Rauscher strain). Blood. 1968 Mar; 31(3):381-7.
Score: 0.000